Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Anodyne Infrared Therapy Coverage | Open…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy MP142

    Anodyne Infrared Therapy

    Customize your policy alerts

    Sign up for Geisinger Health Plan Policy MP142 alerts

    Get alerted when Policy MP142 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Geisinger Health Plan's coverage stance for Anodyne (monochromatic infrared/MIRE) therapy across commercial, Medicare, CHIP and Medicaid business segments and describes related definitions and coding. Affects providers submitting claims or prior authorization requests to Geisinger Health Plan.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyAnodyne Infrared Therapy
    Policy CodePolicy MP142
    Change TypeNo material changes
    Effective DateDec 10, 2004
    Next Review Date
    Key ActionDo not bill Anodyne Infrared Therapy as a covered service because the Plan considers it unproven; consult prior authorization resources when planning services.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Not coveredPlan exclusion
    Covered as heatHeat modality exception
    3 codesInformational codes
    MP142Policy ID
    ~25

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    References

    Coverage Determination

    Coverage stance

    Coverage determination for Anodyne Infrared Therapy:

    Primary exclusion: The Plan does NOT provide coverage for Anodyne Infrared Therapy because it is considered unproven due to insufficient evidence in peer-reviewed literature to establish effectiveness on health outcomes.

    Geisinger Technology Assessment Committee concluded insufficient evidence.

    Medicaid/Heat modality exception: Infrared treatment is covered when medically necessary as a heat modality in a physical therapy regimen (PA Medicaid business segment).

    PA Medicaid applies policy as written; other lines of business follow eligibility, contract-specific benefits, limitations and exclusions and may require case-by-case evaluation.

    The Plan does NOT provide coverage for Anodyne Infrared Therapy because it is considered unproven. The Geisinger Technology Assessment Committee reviewed the technology and concluded that there is insufficient evidence in the peer‑reviewed published medical literature to establish effectiveness on health outcomes compared with established tests or technologies.

    Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Providers should note that unproven services delivered outside of an approved clinical trial are also specifically excluded under the member's certificate.

    Anodyne Infrared Therapy is considered unproven and therefore not medically necessary under this policy due to the lack of sufficient evidence demonstrating improved health outcomes.

    Unproven services that are not part of an approved clinical trial are excluded from coverage under the member's certificate. This policy does not expand coverage to items or services that are specifically excluded by the member's contract; prior authorization and precertification requirements may still apply.

    Billing and Code Listings

    Informational associated codesCPT
    97039Unlisted modality (specify type and time if constant attendance)
    97139Unlisted therapeutic procedure (specify)
    97799Unlisted physical medicine / rehabilitation service or procedure

    Provider Requirements, Prior Authorization, and Billing Notes

    Prior Authorization

    Confirm benefit documents and applicable LOB rules before scheduling

    Coverage and any required review are subject to the member’s line-of-business benefit documents; for Medicare, applicable LCDs/NCDs supersede this policy. For the Pennsylvania Medicaid (PA Medicaid) business segment, this policy applies as written and nonconforming requests may be evaluated case-by-case.

    • Eligibility and contract-specific benefits, limitations and exclusions will apply and supersede this policy when specified.
    • Medicare coverage is governed by LCDs/NCDs; consult CMS or the local MAC for Medicare coding/coverage.
    Prior Authorization

    Check Geisinger prior authorization and precert lists

    Prior authorization and/or precertification may be required per the member’s contract; providers should consult Geisinger’s prior authorization resources before scheduling services.

    • Prior authorization requirements can be found at: https://www.geisinger.org/health-plan/providers/ghp-clinical-policies

    Background

    Anodyne Infrared Therapy, also called Monochromatic Infrared Energy (MIRE), delivers monochromatic near‑infrared photo energy from superluminous gallium aluminum arsenide diode arrays applied in a flexible pad in contact with the skin. The device is proposed to work by releasing nitric oxide from hemoglobin and proteins, which may relax smooth muscle in vessels and lymphatics, and has been marketed and evaluated for indications including chronic nonhealing wounds, diabetic peripheral neuropathy and lymphedema.

    Definitions

    inv-16: Anodyne Infrared Therapy / MIRE definition
    TermAnodyne Infrared Therapy (aka Monochromatic Infrared Energy, MIRE)
    DefinitionDelivery of monochromatic, near-infrared photo energy through contact with the skin via an array of superluminous gallium aluminum arsenide diodes on a flexible pad.
    Proposed mechanismApplication of photo-energy is proposed to release nitric oxide from hemoglobin and other proteins, which may relax smooth muscle in arteries, veins and lymph vessels.
    inv-17: Medical Necessity definition
    TermMedical Necessity (Medically Necessary)
    General definitionCovered services rendered by a Health Care Provider that are appropriate for the symptoms and diagnosis or treatment of the member's condition, and provided for the direct care and treatment of the member's condition.
    Policy Summary
    PayerGeisinger Health Plan
    PolicyAnodyne Infrared Therapy
    Policy CodePolicy MP142
    Change TypeNo material changes
    Effective DateDec 10, 2004
    Next Review Date
    Key ActionDo not bill Anodyne Infrared Therapy as a covered service because the Plan considers it unproven; consult prior authorization resources when planning services.
    SourceLink
    On This Page
    Coverage DeterminationBilling and Code ListingsProvider Requirements, Prior Authorization, and Billing NotesBackgroundDefinitions
  1. Precertification lists are in the member’s contract-specific benefit document.
  2. Documentation Required

    Document medical necessity for heat-modality use in PA Medicaid

    If treating under the PA Medicaid business segment, document medical necessity when using infrared as a heat modality in a physical therapy regimen; nonconforming requests may be evaluated case-by-case.

    • Note the explicit PA Medicaid exception: infrared treatment is covered when medically necessary as a heat modality in a PT regimen.
    • Retain documentation showing why modality is integral to the PT plan of care.
    Denial Risk

    Avoid authorization requests for Anodyne therapy outside the PA Medicaid exception

    Do not request authorization for Anodyne Infrared Therapy as a covered therapy outside of the PA Medicaid heat-modality exception without strong supporting evidence—such requests are subject to denial as unproven.

    • The Plan does NOT provide coverage for Anodyne Infrared Therapy because it is considered unproven.
    • Requests that do not meet PA Medicaid criteria may be evaluated case-by-case but are generally excluded.
    Billing Rule

    Bill with appropriate unlisted modality/procedure codes and specify type/time

    When billing for infrared-type services, include an appropriate unlisted CPT/HCPCS code and specify the modality type and time or other details required by that unlisted code (e.g., 97039, 97139, 97799). Inclusion of these codes is informational and does not guarantee coverage.

    • Use 97039 (Unlisted modality) — specify type and time if constant attendance.
    • Use 97139 (Unlisted therapeutic procedure) — specify the procedure.
    • Use 97799 (Unlisted physical medicine/rehab service) — provide required details.
    Prior Authorization

    Use Geisinger clinical policies and member precert lists for PA instructions

    Providers should consult Geisinger Health Plan’s providers clinical policies page for prior authorization instructions and check the member’s contract-specific precertification lists before scheduling.

    • Prior authorization requirements and clinical policy guidance: https://www.geisinger.org/health-plan/providers/ghp-clinical-policies
    • Precertification lists are in the member’s contract-specific benefit document.
    Denial Risk

    Anodyne Infrared Therapy requests are denied as unproven

    Requests for Anodyne Infrared Therapy will be denied because the Plan considers the therapy unproven due to insufficient evidence of effectiveness in peer-reviewed literature.

    • Geisinger Technology Assessment Committee concluded there is insufficient peer‑reviewed evidence to establish effectiveness.
    • Denials will follow the Plan’s exclusion for Anodyne Infrared Therapy as unproven.
    Denial Risk

    Exclusion risk: experimental/investigational and unproven services are not covered

    Coverage for experimental, investigational or unproven treatments is specifically excluded under the member’s certificate; prior authorization requirements may still apply, and services outside an approved clinical trial are excluded.

    • This policy does not expand coverage to items specifically excluded in the member’s certificate; see MP015 for the evaluation process.
    • Prior authorization and/or precertification requirements for items may apply and precert lists are in the member’s benefit document.
    Standards and intentServices must be in accordance with current standards of good medical treatment, not primarily for convenience, and represent the most appropriate source or level of service for the member.
    Medicaid-specific criteriaFor Medicaid: services that will prevent onset, reduce or ameliorate effects of illness/injury, or help the member achieve or maintain maximum functional capacity are considered medically necessary.
    inv-18: Monochromatic infrared energy (MIRE) / Anodyne therapy summary
    DescriptionA therapeutic approach using monochromatic near-infrared photo energy emitted from diode arrays (infrared heating/light pad systems) applied in contact with the skin to improve sensation, circulation and wound healing in conditions such as peripheral neuropathy and chronic nonhealing wounds.
    Device characteristicsEnergy is emitted by an array of superluminous gallium aluminum arsenide diodes located on a flexible pad designed for contact application to the skin.
    Clinical uses evaluatedEvaluated for chronic nonhealing wounds, diabetic peripheral neuropathy, lymphedema, and other conditions in peer-reviewed studies and technology assessments.
    Evidence summaryGeisinger Technology Assessment and multiple systematic reviews and trials cited (see references) have been considered in assessing effectiveness; policy concludes evidence is insufficient for routine coverage.